Further studies have demonstrated that Spectinabilin(1) increases p21 protein levels (a cyclin-dependent kinase inhibitor located downstream of the p53 gene) by reducing cyclin B1 and cdc2 protein levels, triggering G2/M cell cycle in SMMC7721 human hepatoma and HepG2 cells. Here, TP53 is linked to hepatocellular carcinoma.